Sanofi-GSK Vaccine Launch Delayed to Q4 Next Year... "Insufficient Immune Response in Elderly"
[Asia Economy Reporter Son Sunhee] The release of the novel coronavirus disease (COVID-19) vaccine being developed by French pharmaceutical company Sanofi and British GlaxoSmithKline (GSK) has been postponed until the end of next year.
On the 11th (local time), Sanofi and GSK announced in a press release that "the results of the Phase 1 and 2 clinical trials of the COVID-19 vaccine candidates showed insufficient immune response among adults aged 50 and over." However, the companies explained that adults aged 18 to 49 who received the vaccine candidates showed an immune response comparable to that of COVID-19 recovered patients.
The two companies plan to resume Phase 2 clinical trials around February next year and aim to launch the vaccine in the fourth quarter of 2021.
Hot Picks Today
"Now Our Salaries Are 10 Million Won a Month" Record High... Semiconductor Boom Drives Performance Bonuses at Major Electronic Component Firms
- Experts Already Watching Closely..."Target Price Set at 970,000 Won" Only Upward Momentum Remains [Weekend Money]
- "Heading for 2 Million Won": The Company the Securities Industry Says Not to Doubt [Weekend Money]
- Prime Minister Kim Minseok: "Samsung Electronics Strike Could Cost Up to 1 Trillion Won per Day, 100 Trillion Won Total... Tomorrow's Talks Are the Last Chance" (Comprehensive)
- "Chanel Open Run? I Get a Free Pass"... The World of the Top 0.1% That Money Alone Can't Enter [Luxury World]
Sanofi is developing the vaccine candidates using recombinant DNA technology, which is used in the production of seasonal flu vaccines, while GSK is utilizing adjuvants that enhance immune responses.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
